Advances in payload-linker technology have enabled antibody-drug conjugates (ADCs) to become a major therapeutic modality. In recent years, ADCs have become a crucial component of the anticancer drug toolkit, prompting an increasing number of drug developers to strive for greater selectivity and safety in the next wave of ADC development. Payload-linker selection is crucial to these initiatives, making it essential to work with an experienced development and manufacturing partner when navigating the highly competitive ADC market.
Payload-linker breakthroughs have resulted in a significant increase in ADC activity. In one study, PhRMA tracked a more than 30% increase in the number of ADCs in clinical development between 2018 and 2023. This paper examines the current landscape and offers insights into what companies should look for in a payload-linker provider.
